These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 21097801)

  • 1. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis.
    Salliot C; Finckh A; Katchamart W; Lu Y; Sun Y; Bombardier C; Keystone E
    Ann Rheum Dis; 2011 Feb; 70(2):266-71. PubMed ID: 21097801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy in Poland].
    Samborski W; Buczek J; Bednarek A; Lewandowicz J; Kucharz E
    Pol Merkur Lekarski; 2010 Dec; 29(174):365-8. PubMed ID: 21298986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
    Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
    Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
    Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
    Isaacs JD
    Expert Opin Biol Ther; 2009 Dec; 9(12):1463-75. PubMed ID: 19916731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials.
    Thompson AE; Rieder SW; Pope JE
    Arthritis Rheum; 2011 Jun; 63(6):1479-85. PubMed ID: 21360522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
    Belmonte Serrano MA; Pincus T
    Rheumatology (Oxford); 2010 Sep; 49(9):1795-6; author reply 1796-7. PubMed ID: 20484342
    [No Abstract]   [Full Text] [Related]  

  • 10. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.
    Kapetanovic MC; Saxne T; Nilsson JA; Geborek P
    Rheumatology (Oxford); 2007 Apr; 46(4):608-11. PubMed ID: 17114801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis.
    Bukhari M; Abernethy R; Deighton C; Ding T; Hyrich K; Lunt M; Luqmani R; Kiely P; Bosworth A; Ledingham J; Ostör A; Gadsby K; McKenna F; Finney D; Dixey J;
    Rheumatology (Oxford); 2011 Dec; 50(12):2311-3. PubMed ID: 21546351
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial.
    Tak PP; Rigby WF; Rubbert-Roth A; Peterfy CG; van Vollenhoven RF; Stohl W; Hessey E; Chen A; Tyrrell H; Shaw TM;
    Ann Rheum Dis; 2011 Jan; 70(1):39-46. PubMed ID: 20937671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Targeting CD20 in rheumatoid arthritis].
    Saito K; Tanaka Y
    Nihon Rinsho; 2007 Jul; 65(7):1243-9. PubMed ID: 17642239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial.
    Haraoui B; Bokarewa M; Kallmeyer I; Bykerk VP;
    J Rheumatol; 2011 Dec; 38(12):2548-56. PubMed ID: 21965646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TNF inhibitors in the treatment of arthritis.
    Lorenz HM
    Curr Opin Investig Drugs; 2000 Oct; 1(2):188-93. PubMed ID: 11249572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab therapy in rheumatoid arthritis in daily practice.
    Assous N; Gossec L; Dieudé P; Meyer O; Dougados M; Kahan A; Allanore Y
    J Rheumatol; 2008 Jan; 35(1):31-4. PubMed ID: 18176989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
    Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
    Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses.
    Behrens F; Koehm M; Burkhardt H
    Curr Opin Rheumatol; 2011 May; 23(3):282-7. PubMed ID: 21427581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rituximab (Mabthera)--treatment of rheumatoid arthritis patients with inadequate response to TNF inhibitors--when to change therapy?].
    Morović-Vergles J
    Reumatizam; 2008; 55(2):70-2. PubMed ID: 19024280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Tijhuis GJ; van de Putte LB; Breedveld FC
    Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1880-5. PubMed ID: 11605312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.